FDA Approval Sought for Tucatinib in HER2+ Breast Cancer

A new drug application has been submitted to the FDA for tucatinib for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Read the full article here

Related Articles